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ABSTRACT 
 
Background: The prevalence of childhood obesity has increased dramatically in the United 
States, disproportionately afflicting racial and ethnic minorities and producing lifelong health 
consequences.  Various lifestyle and pharmacologic obesity interventions have been analyzed 
with inadequate representation of minority populations.  Systematic reviews that address obesity 
interventions in minority populations have not been published.  Even with the increasing 
research on pediatric obesity, many clinicians and public health professionals are uncertain of 
effective interventions in minority populations.          
Purpose:  To identify pediatric obesity intervention studies in minority populations and assess 
the effectiveness of these interventions.   
Data Sources:  The MEDLINE database (inception through February 2008). 
Study Selection:  The author selected prospective studies of various pediatric obesity 
interventions with adequate racial and ethnic minority participation that reported an outcome 
related to body mass index.  
Data Extraction:  Predefined criteria were used to extract details on study design, study 
duration, study population, intervention type and outcomes.  The studies were then graded as 
good, fair or poor.  The overall body of evidence was then graded as high, moderate or low.    
Results:  Ten eligible articles were included in the systematic review, seven of which were 
randomized controlled trials (RCT), one of which was a secondary analysis of an existing RCT, 
and two of which were prospective cohort studies.  African-American and Hispanic children 
were the most common minority population represented.  Five studies were effective in reducing 
adiposity.  Only two studies were graded as good, while many had serious methodological flaws.  
Moderate evidence exists for some pharmacological interventions in decreasing adiposity, but 
evidence for lifestyle interventions alone is limited.   
Conclusions:  Studies that address racial and ethnic minorities are limited.  Available evidence 
does not clearly support any obesity intervention in minority populations, although 
pharmacotherapy in patients at high risk for comorbidities or combined with lifestyle changes 
may offer some benefit. 
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INTRODUCTION 
 
Background  
Obesity is a significant public health crisis that affects all ages, racial and ethnic groups.  
The prevalence of overweight and obesity in children in the United States has increased 
dramatically over recent years, disproportionately affecting minority groups and contributing to 
existing racial and ethnic health disparities.  According to recent estimates, about 34% of 
children, ages two to nineteen, are considered overweight or at risk of overweight.1  Between 
1963 and 2000, the prevalence of overweight in children aged six to eleven increased from 4% to 
15.3% and from 5% to 15.5% among adolescents in the United States.2  The prevalence of 
overweight in adolescents increased in each racial group from 1988 to 2000, according to the 
National Health and Nutrition Examination Survey (NHANES), with the most significant 
increase in non-Hispanic blacks (13.4% to 23.6%) and Mexican Americans (13.8%-23.4%).3  
Children ages six to eleven years of age also experienced similar prevalence trends in racial 
groups.2  Although overweight and obesity affect all children, the prevalence rose more than 
twice as fast among minority groups compared with white groups in the United States.4   
 
Measurement of Overweight/Obesity 
The body mass index (BMI) has been accepted as an indicator for overweight and obesity 
in children5, 6 and is predictive of obesity risk as an adult.7  BMI has also been shown to correlate 
with actual body fat in children and adolescents.8, 9  One study found that the BMI or the BMI 
percentile are optimal measures in assessing change in adiposity as a child grows.10  In 2000, the 
Centers for Disease Control and Prevention first designated the term, overweight, to children, 
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ages two to eighteen, with a body mass index at or above the 95th percentile for age and sex, and 
those children with a BMI between the 85th and 95th percentile for age and sex were termed at 
risk for overweight.5, 11  This terminology has recently been revised by an expert committee who 
published recommendations to consider greater than the 95th percentile as obese and between the 
85th and 95th percentiles as overweight.12   The term obese had not been designated as a weight 
category in childhood before prior to this change in terminology.  This change strengthens the 
clinical relevance of BMI measurement, is more continuous with adult measures and better 
reflects the seriousness of associated health consequences.12 
 Body mass index is commonly used to classify children as overweight or obese, but 
measuring the change in BMI over time is less straightforward.  Researchers have investigated 
various methods to track change in body mass index and have demonstrated differences in the 
individual measures.13  This is a significant consideration when determining the effectiveness of 
an intervention based on a single measure.  When children are still growing, the absolute change 
in BMI is not an accurate measure of treatment effect,13 and other measures are more 
informative.  However, this may have less influence in BMI monitoring in adolescents since 
growth has slowed.  Obesity intervention studies have analyzed changes in absolute BMI, 
percent BMI, BMI z-score, BMI centile,10 percent over-BMI and BMI sympercent.13  One study 
found that BMI and percent BMI are superior measures, since BMI z-score can get progressively 
smaller the more obese the child.10  Although BMI z-score is still considered a valuable tool to 
measure overweight in children, the percent over-BMI is recommended in clinical decision 
making and showing changes in obesity interventions.13  Many studies provide more than one 
measure to better reflect changes in adiposity over time.       
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Causes  
Pediatric obesity is largely caused by an imbalance between energy intake and 
expenditure with inadequate physical activity and poor nutrition with excess calorie-dense 
foods.14  Although studies suggest that genetics may have a significant influence on individual 
risk,15 the widespread, dramatic increase in childhood obesity is more likely related to behavior 
changes and environmental factors than genetic modification.6  The complex interaction between 
genes, environment and behavior lead to chronic obesity, which is associated with substantial 
health consequences that continue throughout one’s life-course. 
Racial and ethnic minority children and adolescents are disproportionately affected with 
higher rates of obesity.16  Studies have shown that low socioeconomic status is associated with 
higher rates of overweight and obesity.17, 18  Urban populations, in particular, appear more 
susceptible because of poor diet19 and limited opportunity for physical activity.20  Current 
research addressing the causes and associated factors that contribute to obesity are still being 
investigated, including the possible protective effects of breastfeeding, independent of racial and 
socioeconomic group.21   
 
Health Consequences 
A wide array of literature has examined the burden of pediatric obesity, associated health 
outcomes, the trends in prevalence among different racial and ethnic groups, and options for 
prevention and treatment of pediatric obesity.  Long-term health consequences, in particular, are 
of significant concern since overweight children have a higher risk of being overweight 
adolescents22 and overweight adults.23  With increasing rates of obesity, Type 2 diabetes is a 
serious health consequence that has also increased among children.  In the United States, studies 
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have estimated that 8 – 43% of new-onset diabetes cases in the pediatric population are 
considered Type 2 diabetes mellitus.24  The SEARCH for Diabetes in Youth Study Group, who 
intended to provide the most comprehensive data to date on diabetes prevalence in children, 
found 6379 cases out of about 3.5 million children and adolescents.  For youths 10 – 19 years of 
age, the crude prevalence was 2.80 cases per 1000 youths, while the crude prevalence was less in 
children aged 0 – 9 years, estimated at 0.79 cases per 1000 children.25  Minorities, including 
Native Americans, African-American, Hispanic and Pacific Islander/Asian children, are at higher 
risk of developing this chronic disorder.  For example, 76% of new diabetes cases diagnosed in 
Native American children aged 12-19 years were identified as Type 2 diabetes mellitus.25  
Children with diabetes are at risk for heart disease, stroke, limb amputations, kidney failure and 
blindness, all of which are consequences of long-standing diabetes.  Other complications of 
pediatric obesity include sleep apnea26, asthma27 and exercise intolerance28, in addition to serious 
hepatic, renal, musculoskeletal and neurological complications.29-32   
Since childhood obesity frequently continues into adulthood, it is a contributor to the 
adult obesity epidemic and its associated morbidity and mortality.33  As in adults, obesity in 
childhood is associated with increased incidence of cardiovascular disease risk factors, such as 
hypertension, dyslipidemia, chronic inflammation, increased blood clotting tendency, endothelial 
dysfunction and hyperinsulinemia.34  These complications are considered components of the 
insulin resistance syndrome (IRS), which has been identified in children as young as age five.35  
The metabolic effects of the insulin resistance syndrome may differ by race or ethnicity.  
Caucasian children were shown to have significantly more visceral fat, which is associated with 
IRS, when compared to African-American children.  However, independent of visceral fat, 
African-American children were shown to be more insulin resistant.36, 37  These differences 
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require more research to better understand the influence of racial and ethnic disparities in 
pediatric overweight and obesity, as well as illustrate the importance of effective obesity 
interventions in minority children to prevent harmful health outcomes.   
Overweight and obese children or adolescents may also experience psychological 
problems such as negative self-esteem, withdrawal from peer interaction, depression, anxiety and 
the feeling of chronic rejection,38 as well as significantly lower quality of life.39-41  Obese 
adolescents with lower self-esteem were also shown to have higher rates of loneliness, sadness, 
nervousness, as well as an increased risk of smoking and drinking alcohol.42  In addition, obese 
Hispanic and white females were shown to develop significantly lower self-esteem by early 
adolescence than those who were not obese.42  The extensive multi-system health consequences 
associated with pediatric obesity require effective prevention and treatment interventions in 
childhood, as well as life-long management.   
 
Additional research needed 
Although obesity prevention is crucial, a significant number of children are already 
overweight or obese and experience health consequences as a result.  The complexity and 
difficulty of managing childhood obesity and its complications, such as type 2 diabetes mellitus, 
leave many primary care providers uncomfortable with treatment options.43  Additionally, 
primary care providers often lack the time and resources to offer intensive interventions and have 
few opportunities for referral.44  As a result, providers and the public health community are in 
need of evidence-based interventions that are effective in addressing pediatric obesity.  Some 
studies aim to provide guidance and recommendations for managing pediatric obesity, but few 
address racial, ethnic or cultural concerns associated with this health problem.  Many existing 
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studies assess intervention effects on homogeneous populations.  Even with the increasing 
amount of literature regarding pediatric obesity interventions, disparities continue to widen with 
higher prevalence in Mexican-American boys and African-American girls.1  Considering 
overweight interventions have been shown to be less effective in minority populations than in 
whites,45 or studies fail to include adequate representation of different racial and ethnic groups, 
effective interventions that are sure to include all racial or ethnic groups are necessary to prevent 
growing disparities.  Therefore, the aim of this paper is to conduct a systematic review 
examining the effectiveness of interventions in childhood overweight and obesity in racial and 
ethnic minorities. 
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METHODS 
 
Inclusion Criteria 
 The goal of this systematic review was to identify interventions designed for childhood 
overweight and obesity and assess their effectiveness in minority populations.  The purpose is to 
determine if specific interventions will work in populations other than Caucasian/white, and not 
compared to this population.  Types of interventions in this review include: pharmacologic 
treatment, surgical treatment, lifestyle changes (dietary, physical activity, behavioral) or a 
combined therapy.  Studies can assess effects by comparing the intervention to another treatment 
or to no intervention.  Clinical, community or school-based interventions were included and 
there was no restriction on who was delivering the intervention.     
Randomized controlled trials were included in the review if they analyzed an intervention 
of at least 12 weeks in duration.  Observational studies were included if they had at least 50 
participants and the intervention was at least 6 months in duration.   
 No comparison between racial or ethnic groups was required.    No limit was placed on 
how many racial/ethnic groups were addressed in a particular study and one group was 
considered sufficient.  To assess these interventions in minority populations, studies that only 
address minorities as a specific objective or identified minorities in the study were included for 
review.  If a study did not focus on a specific minority group, then the baseline characteristics 
should have reflected at least 40% of the study participants in a racial or ethnic group other than 
Caucasian or white.  There was no standard cut-off determined for adequate minority 
representation, so this percentage was arbitrarily chosen to be more than population 
representation, but less than majority since a majority may have narrowed results dramatically 
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due to the under-representation of minorities in research studies.  African-American, Hispanic, 
Asian, Alaska native/Native American, or Other, were possible racial/ethnic categories to 
identify study participants, although African-American and Hispanic participants were more 
commonly included.  Since this review focuses on treatment and not on prevention, the study 
must have enrolled overweight or obese participants at baseline, with a BMI > 85% for age and 
gender.  However, articles were not excluded if normal-weight children also participated.  All 
children under age 18 at the start of the study were included in this review.    
To be included in the review, the study must have assessed some outcome of weight, 
including baseline and post-intervention height and weight, body mass index (BMI), BMI 
percentile change or BMI z-score.   
 
Exclusion Criteria 
 Studies were excluded from the review if they did not meet the predetermined inclusion 
criteria outlined above.  Studies that included children with chronic diseases (other than Type II 
diabetes mellitus), psychiatric co-morbidities or children taking a medication that affects weight 
control (i.e. anti-psychotics or corticosteroids) were excluded.  Studies that included participants 
with Type II diabetes were not excluded since this condition is often associated with obesity and 
can lie on a continuum for severely obese youth may already have aspects of the metabolic 
syndrome prior to developing diabetes.  These participants especially are in critical need of 
effective interventions for obesity to help treat the condition, although obesity interventions prior 
to this point of health consequences are preferable.  Any study that dealt with eating disorders 
(anorexia nervosa, bulimia) was also excluded, as well as studies that dealt with weight control 
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for pregnant females.  In addition, organic or syndromal causes of obesity, such as the genetic 
syndrome, Prader-Willi, were excluded from this review.   
 
Table 1: Eligibility Criteria 
Study design 
• Randomized controlled trial ≥ 12 week intervention OR 
• Observational studies with at least 50 participants and 
duration ≥ 6 months. 
Study population 
• Overweight or obese* children, ages 0-18. Did not exclude 
articles that contained normal weight participants, as long a 
majority of overweight or obese participants were included. 
• Article addresses specific minority group OR includes ≥ 40 
% racial/ethnic minority group (African-American, 
Hispanic, Asian, Native American, etc.) 
• Children with BMI < 85th percentile accepted if separate 
analysis than those with ≥ 85th percentile 
Study intervention 
• Any clinical or community intervention, including 
behavioral, pharmacotherapy, surgical, etc. 
Outcome measure 
• Body mass index (BMI) 
• BMI percent change 
• BMI z-score 
* The terms, overweight and obese, are used to reflect the most recent recommendations in terminology12 and 
includes children with a BMI ≥ 85th and ≥ 95th percentile respectively.  Studies may identify these participants as at 
risk for overweight and overweight, but still refer to a BMI ≥ 85th percentile or ≥ 95th percentile.     
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Literature Search Strategy 
 In order to find articles that addressed the key question, I performed a MEDLINE 
electronic database search, using PubMed, from inception through February, 2008.  All searches 
were limited to children, ages 0-18, to concentrate on the pediatric population, and articles in the 
English language.  The search strategy began with the MeSH term, “overweight” or “obesity,” 
although the latter term should be included in the first term.  Both terms were used at first, but 
the remaining searches utilized “overweight” since it better reflected the terminology used in 
much of the pediatric literature since a BMI > 95th percentile was considered “overweight” until 
recently, yielding a more sensitive search.  To find studies on treatment or intervention, the 
subheading, “therapy” was used in conjunction with “overweight.”  This primary search for 
overweight yielded 4708 articles.  To focus on minority population interventions, I searched 
“African-Americans” and “Hispanic” MeSH terms.  The search for overweight therapy was 
combined with the search for African-American or Hispanics, yielding 132 articles.  In order to 
include articles that may include the general term, “minorities,” a search for overweight therapy 
and minorities was used and yielded 61 articles.  A final search included overweight therapy and 
African-American or Hispanic populations or overweight therapy and minority populations, 
yielding a total of 177 articles.  Of these, 29 articles were randomized controlled trials (using 
clinical queries).  I conducted a title review of all 177 articles and found 99 applicable articles.  I 
excluded 98 articles that clearly were not relevant to the topic or addressed a topic included in 
the exclusion criteria.  I conducted an abstract review of the 99 articles, followed by a full article 
review of 28 articles.   
 In addition to articles that explicitly addressed minority populations, I searched for 
general childhood overweight articles that enrolled participants of different races and ethnicities.  
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A search for overweight therapy for children, ages 0-18, again yielded 4708 articles.  From these, 
I limited the search to 447 randomized controlled trials.  I conducted a title review and excluded 
328 articles that did not address the key question, included adults, or clearly contained one or 
more of the exclusion criteria.  I then conducted an abstract review of the remaining 119 articles, 
followed by a full article review of 40 articles (overlap with the previously reviewed 28 articles).    
 I also hand-searched the reference lists of background articles for potentially relevant 
studies that may have been missed with the search strategy.  The search was repeated multiple 
times from the start to ensure reproducibility and strength of the search strategy.   
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Figure 1: Article Selection 
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Data Extraction and Quality Assessment 
 I extracted data from each study in the review, including characteristics of participants 
(number of participants, racial/ethnic group, age range, baseline BMI, etc), type of intervention 
(clinical, school-based, community), magnitude of effect/ outcomes, adverse events, study design 
and quality of study.  To assess internal validity of randomized controlled trials, I used 
predefined criteria used by the U.S. Preventive Services Task Force to grade each study as good, 
fair or poor.46  For example, these guidelines consider the following characteristics of a 
randomized controlled trial: comparable groups with adequate randomization and concealment of 
allocation; maintenance of comparable groups throughout the study; differential or high loss to 
follow-up; equal, reliable and valid measurement; clear definition of intervention and appropriate 
analysis.  The internal validity and quality of observational studies were assessed by the criteria 
summarized by Deeks et al.47  External validity is discussed, but did not affect the quality rating.  
Additional information on the grading criteria is found in Appendix A.   
 
Data Synthesis 
 Since the interventions varied widely and some focused on a specific racial or ethnic 
group alone, I will concentrate on a qualitative synthesis by describing each study, results and 
limitations, rather than performing a quantitative analysis. 
 
Rating of the Overall Strength of Evidence 
 Overall strength of the evidence was rated as very low, low, moderate or high, as shown 
in Table 2.  The ratings are based on the definitions and recommendations outlined in the 
GRADE Working Group paper,48 which incorporates the following key elements to guide the 
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quality review: study design, study quality, consistency and directness.  This approach provides a 
systematic way of grading the quality of evidence and remains consistent with other systematic 
reviews. The grade reflects the strength of the body of evidence for the efficacy of the different 
types of pediatric obesity interventions.  Directness was not addressed in this review since all 
potential articles were required to address the effectiveness of an intervention with 
predetermined outcome measures and were therefore considered direct.   
 
Table 2.  Definitions in grading the overall quality of evidence 
Grade Definition 
High Further research is very unlikely to change our 
confidence in the estimate of effect. 
Moderate Further research is likely to have an important 
impact on our confidence in the estimate of 
effect and may change the estimate.  
Low Further research is very likely to have an 
important impact on our confidence in the 
estimate of effect and is likely to change the 
estimate. 
Very Low Any estimate of effect is very uncertain. 
Source: Grade Working Group48 
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RESULTS 
Using the search strategy outlined in the methods section, ten studies were identified that 
met the inclusion criteria.49-58  All eligible studies were included independent of quality, but are 
assessed based on the pre-established quality criteria.  Seven studies were randomized controlled 
trials,49, 51, 52, 54, 56-58 one study was a secondary analysis of an existing randomized controlled 
trial50 and two were observational studies.53, 55  Studies addressed various age ranges with an 
overall span of age eight to eighteen.  All studies looked at interventions in racial and ethnic 
minorities, and most commonly focused on African-Americans and Hispanics.  Four studies 
focused on one particular racial/ethnic group alone,52, 54, 55, 58 two of which concentrated on 
African-American females55, 58 and two on Hispanic youth.52, 54  Participant characteristics of 
included studies are summarized in Table 2.   
There were a variety of interventions offered in the included studies.  Six studies included 
a behavioral intervention that promoted changes in eating and physical activity habits, three 
studies examined the effects of pharmacotherapy and two studies investigated the combination of 
a behavioral intervention with pharmacotherapy. All randomized controlled trials offered at least 
the standard of care to the control group.  No surgical intervention studies were found that met 
the inclusion criteria for racial and ethnic minority participation.   
Of the four studies that evaluated pharmacotherapy,49, 50, 52, 57 two were funded by 
pharmaceutical companies,49, 50 one was funded by research grants57 and one was not reported.52          
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Table 3: Characteristics of Included Studies  
 
Author 
Year 
Mean BMI (kg/m2) 
% overweight or obese* Participants 
Age, 
years 
 
Berkowitz et al 
200649 
 
100% obese 
( ≥ 2 units above 95th 
percentile) 
N = 498 
56.0% White (n = 206) 
21.7% African-American (n = 80) 
16.3% Hispanic (n = 60) 
6.0% Other (n = 22) 
12 – 16 
Budd et al 
2007 50 100% overweight/obese
 
N = 82 
54.9% White (n = 45) 
41.5% African-American (n = 34) 
1.2% Hispanic (n = 1)† 
2.4% Other (n = 2)† 
13 – 17 
Ebbeling et al 
2006 51 44% overweight 
N = 103 
35.9% White (n = 37) 
64.1% Non-white (n = 66) 
17.5% Hispanic (n = 18) 
13 – 18 
García-Morales 
et al 2006 52 100% obese 
N = 46 
100% Hispanic 14 – 18 
Germann et al 
2006 53 100% obese 
N = 150 
88% African-American (n = 132) 
6% Hispanic (n = 9) 
6% Other (n = 9) 
8 – 18 
Johnston et al 
2007 54 100% overweight/ obese 
N = 60 
100% Hispanic 10 – 14 
Resnicow et al 
2000 55 100% overweight/ obese 
N=57 
100% African-American 11 – 17 
Savoye et al 
2007 56 100% obese 
N = 174 ‡ 
36.8% white (n = 64) 
38.5% African-American (n = 67) 
24.7% Hispanic (n = 43) 
8 – 16 
Srinivasan et al 
200657 100% obese 
N = 28 
25% White (n = 7) 
64% Non-white (n = 18) 
11% Mixed background (n = 3) 
9 – 18 
Williamson et al 
2006 58 100% overweight/ obese 
N = 57 
100% African-American 11 – 15 
*Overweight defined as a BMI ≥ 85th percentile and obese defined as a BMI ≥ 95th percentile. 
† Due to the small n, these participants were excluded from the secondary analysis. 
‡ 209 participants originally randomized, but structured meal plan group (n = 35) discontinued due to the high drop-
out rate (83%). 
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Studies Examining Pharmacotherapy Interventions 
 Two randomized controlled trials,52, 57 assessed the effects of pharmacotherapy compared 
to placebo in obese participants, summarized in Table 3.  Both studies only enrolled those 
children who were considered obese, with a body mass index equal or greater than the 95th 
percentile for age and gender and were referred to an endocrine clinic.  One study52 found no 
significant difference between placebo and pharmacotherapy, whereas the other study57 found 
pharmacotherapy to be significantly better than placebo.  One of the RCTs compared placebo 
with sibutramine (Meridia®), a serotonin and norepinephine reuptake inhibitor that has been 
shown to aid in weight loss and weight maintenance in obese adults,59-61 and has been the subject 
of investigation in obese adolescents.49, 62  The other RCT studied the effects of metformin, a 
drug that is used in the treatment of Type II diabetes mellitus and can benefit youth with this 
chronic condition.63  The role of metformin in weight loss and insulin sensitivity prior to the 
development of Type II diabetes has been analyzed in adults,64 and increasingly in adolescents.57, 
65-69  However, only two identified articles utilizing metformin for weight control included a 
sufficient number of minority participants,57, 67 one of which met inclusion criteria for this 
systematic review.  Although the objective in both studies was to assess the effects of 
pharmacotherapy and not lifestyle changes, both trials offered information on healthy eating 
habits and physical activity but did not measure the effects. 
 García-Morales et al randomized 51 obese Mexican children to a trial of sibutramine 
10mg daily or placebo for 6 months.  However, only 46 children were included in the analysis 
since 5 participants dropped out early (3 treatment, 2 placebo).  The study finished with a 90-
100% compliance rate, and had a 24% non-differential dropout rate, with 11 children 
withdrawing (5 from sibutramine group, 6 from placebo group).  In addition to sibutramine or 
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placebo, all subjects were given individualized dietary and physical activity advice.  The 
investigators assessed the safety of sibutramine use in adolescents and reported a small number 
of adverse events, including elevated blood pressure and heart rate, headache, dry mouth, nausea, 
weakness and paleness.  None of the side effects warranted discontinuation.  Although both 
groups experienced clinically significant weight loss, the difference between the sibutramine and 
placebo group was not statistically significant.  The study by García-Morales et al was rated fair 
due to the high post-randomization exclusions (11%) and the lack of a true intent-to-treat 
analysis.   
 Srinivasan et al randomized 28 participants in a 12-month cross-over study to receive 
metformin, 1 g twice daily, vs. placebo for 6 months each, after a two-week wash-out period.  
Although this review only focuses on the effects of treatment on anthropometric measures, this 
study assessed insulin sensitivity and safety of sibutramine as well.  The study population was at 
higher risk of obesity complications, as reflected by acanthosis nigricans in 89% of participants, 
a clinical feature of insulin resistance.  After 6 months of treatment, those subjects receiving 
metformin showed a significant beneficial effect over placebo in weight, weight z-score, BMI, 
BMI z-score and waist circumference, as well as a benefit in fasting insulin and a small benefit in 
fasting glucose.  The change in insulin sensitivity was not significant between groups, a finding 
that the authors associated possibly to the inadequate loss of visceral fat.  Only 2 younger 
participants were not able to tolerate metformin 1 g twice daily due to nausea, but did well with 
750mg twice daily.  Median adherence for both groups was 78%, which may reflect real-life 
compliance with treatment.  The drop-out rate was 14.3%.  This study by Srinivasan et al was 
rated good without serious methodological flaws.  
   
 21
Table 4. Summary of Pharmacotherapy Interventions 
Author, year Study 
design/ [N]/ 
Study 
duration 
Intervention Outcome 
measure 
Results Quality 
Rating 
García-Morales 
et al, 200652 
RCT 
 
46 
 
6 months 
Sibutramine 
10mg daily 
vs. placebo 
Body weight, 
BMI and % 
BMI 
Sibutramine 
Weight: –7.3kg [95% 
CI –4.6 to -9.9] 
BMI: –3.2 kg/m2 [–2.3 
to –4.1 kg/m2] 
%BMI: –9.2 [–6.9 to –
11.6] 
 
 
Placebo 
Weight: –4.3kg [95% 
CI –1.7 to –6.9] 
BMI: –2.0 kg/m2 [–0.9 
to –3.0 kg/m2] 
%BMI: –5.2 [–2.4 to –
7.9] 
 
P > 0.05 
Fair 
Srinivasan  
et al, 200657 
RCT, 
crossover 
 
28 
 
6 months  
Metformin 1g 
twice daily vs. 
placebo 
Weight, 
BMI, BMI z-
score, body 
composition, 
insulin 
sensitivity 
Difference (metformin 
vs. placebo): 
Weight: – 4.35 kg  
BMI: – 1.26 kg/m2 
BMI z-score: – 0.12  
Good 
 
 
Studies Examining Behavioral Interventions 
 The majority of the reviewed literature examined behavioral interventions, focusing on 
diet, physical activity and nutrition education.  Six studies assessed behavioral interventions that 
focused on lifestyle changes,51, 53-56, 58 four of which were randomized controlled trials.51, 54, 56, 58  
Results are summarized in Table 4.  All except one study51 focused on children or adolescents 
who were already overweight or obese, with a body mass index of at least the 85th percentile for 
age and gender.  Five of the studies were intensive lifestyle interventions53-56, 58 and one study 
 22
focused only on a specific behavioral modification.51  Two of the intensive lifestyle interventions 
were family-based,56, 58 one of which utilized the internet to deliver the intervention.58   
 The least intensive intervention focused on decreasing sugar-sweetened beverages in the 
diet to bring about weight loss and found no overall significant difference in the effect on BMI.  
Ebbeling et al randomized a diverse group of 103 adolescents (47 males and 56 females) who 
regularly drank sugar-sweetened beverages to an intervention group that received weekly home 
delivery of non-caloric beverages for 25 weeks vs. a control group that continued usual beverage 
intake behavior.  Baseline characteristics of the participants were compared using gender, race, 
ethnicity, age, household income, household size, weight, height and body mass index (BMI), 
and did not differ except that the intervention group was slightly heavier.  In addition, they did 
not differ in baseline daily intake of sugar-sweetened or non-caloric beverage intake, physical 
activity, television viewing or total media time.  The subjects received enough beverages for the 
household and could choose which types of drinks, such as bottled water or “diet” drinks (soft 
drinks, ice tea, lemonade, punch, etc).  Subjects also received advice on beverage selection when 
they were away from home.  The investigators examined the change in sugar-sweetened 
beverage consumption, as well as BMI. No other measure of BMI was reported to compensate 
for growth, but participants were adolescents, ages 13-18.  Participants were asked to recall 
dietary intake and physical activity with random telephone surveys.  Although these interviews 
relied on recall and may be subject to bias, the adolescents participated in group training sessions 
to learn how to estimate portion sizes and measure intensity of physical activity. This study had a 
100% completion rate and the consumption of sugar-sweetened beverages decreased by 82% in 
the intervention group.  Although no overall significant difference in BMI was found, they 
considered the baseline BMI to be an effect modifier and found a significant change in BMI in 
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those subjects with higher BMI’s to start.  Therefore, the investigators concluded that this 
intervention could decrease sugar-sweetened beverage consumption and may have a beneficial 
effect on body weight and BMI with increasing body weight.  The investigators blinded the 
phone interviewers, but did not report if those measuring BMI outcomes were blinded.  In 
addition, without blinding of the participants and the reliance on recall, the subjects could be 
pressured to provide expected results during the phone interviews.  Strengths of this article were 
the relatively simple intervention and the 100% completion rate, not seen in any of the other 
studies.            
 The studies by Germann et al, Resnicow et al, Williamson et al, Johnston et al, and 
Savoye et al, were similar in that they provided a multi-disciplinary intensive behavioral 
intervention that focused on healthy eating habits and increasing physical activity, the mainstay 
of weight loss.  As expected with intensive interventions, the drop-out rate was much higher.  
Three of the studies had a 40% or greater drop-out or loss to follow-up rate,53, 55, 56 whereas one 
study had a 95% completion rate.54  One study53 had only 23% of participants achieve clinically 
significant weight loss and another study55 demonstrated increased weight and BMI after the 
intervention.  Three studies had positive results, one of which54 showed a significant decrease in 
weight, BMI and standardized BMI over control, another study56 showed a significant decrease 
in BMI and percent body fat over the control group and the last study58 found significant percent 
body fat loss at 6 months but not at 2 years.         
 Germann et al provided cognitive-behavioral therapy, nutritional education, medical 
monitoring and structured exercise training as part of the program, FitMatters,  to a group of 150 
low-income minority children (ages 8-18) for one year, 23% of whom achieved weight loss.  Of 
these initial participants, only eighty-three (55%) were able to participate in the follow-up study 
 24
to assess weight loss at an average of 23 months after the initial assessment.  This study took a 
more psychological approach by conducting an initial psychological assessment on each family, 
providing cognitive-behavioral techniques, such as self-monitoring, stimulus control, anxiety 
management, coping and relapse prevention, and measuring the following outcomes: consistency 
of child and parent self-monitoring, behavioral and emotional stability and the degree of 
perceived familial conflict.  Weight control behaviors, exercise levels and eating behaviors were 
also noted.  Studying correlates of success may provide guidance in the design or 
implementation of a particular intervention.  The participants, non-participants and comparison 
group had similar baseline measures in socioeconomic status, age, ethnicity, initial BMI, 
intellectual functioning or child and parental self-monitoring.  The comparison group was used to 
look at the rate of weight gain before and after participating, but the comparison group may have 
differed from those participants for whom previous records did not exist.  The investigators 
designated a change of – 0.70 in BMI z-score as the cutoff for “clinically meaningful weight 
change,” which nineteen participants (23%) achieved, and compared these “successful” 
participants with “less successful” participants.  Those who were successful in achieving 
meaningful weight change were observed to participate in more sessions over a longer period of 
time, be slightly heavier before the program and have better weight control skills.  However, 
these results should be interpreted cautiously.  This study was rated poor due to the overall high 
loss-to-follow-up (44.7%), lack of comparison group, potential differences between those 
participants that were lost-to-follow-up and their risk of obesity, unequal time of follow-up 
among participants with no mention of adjusting for individual length of follow-up and no 
mention of blinding of the outcome assessors.  
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 Like the previous study by Germann et al, Resnicow et al took a social cognitive theory 
approach to a 6-month intensive intervention in severely obese African-American females but 
did not demonstrate any improvement in BMI.  The study observed 57 youth recruited from 
inner-city public housing developments.  The participants received dietary and exercise 
guidance, focused mainly on increasing fruit and vegetable intake, decreasing fat intake, 
decreasing fast food intake, decreasing television viewing and increasing physical activity.  The 
program also worked to reinforce a positive and healthy outlook, decrease negative expectations, 
and increase confidence in their abilities to change lifestyle, including hands-on cooking 
experience.  On average, the participants attended 43% of the sessions.  The investigators 
compared high and low attendees but found no significant difference in BMI and both groups 
showed an increase in body weight and BMI.  This study was rated poor due to the high overall 
loss-to-follow-up (45%), little adjustment for confounding and potential selection bias and use of 
high and low attendees as comparison groups, which may have important differences.       
 Williamson et al also concentrated on weight loss in African-American females, but 
rather than a community-based program like the previous study, the investigators evaluated an 
internet-based lifestyle intervention for 2 years.  A slight benefit in percent body fat was 
demonstrated in the intervention group at 6 months without changes in BMI, but groups were no 
different at 2 years.  Fifty-seven participants were randomized to an interactive internet weight 
loss program or to a passive internet-based health education program as the control.  The girls 
had to have an overweight parent who was willing to participate in the study.  The intervention 
included interactive nutrition education, counseling and behavior medication through the internet 
and email, focusing on eating habits and physical activity, in addition to four in-person 
counseling sessions during the first 12 weeks.  The control group differed in that no counseling 
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or recommended behavioral changes were offered, but only nutrition and exercise education.  
The intervention group had a significant decrease in the percent body fat in the first 6 months, 
but did not significantly differ at 2 years.  Average body mass index increased slightly for both 
groups, but to a lesser extent in the treatment group.   The more long-term follow-up is a strength 
of this study with weight maintenance implications.  This study was rated poor due to the high 
overall loss-to-follow-up (30%), lack of information on randomization scheme and baseline 
characteristics of study participants and no blinding of outcome assessors.               
 Johnston et al evaluated a culturally-appropriate, intensive behavioral intervention in 
Mexican-American children in Houston, Texas and found significant decreases in weight, BMI 
and standardized BMI when compared to the self-help group.  After recruitment, 60 children 
were randomized to receive a school-based, instructor-led intervention (n = 40) vs. a self-help, 
parent-guided manual, Trim Kids, as a placebo (n = 20).  Each group was in a separate classroom 
during the school day.  The intervention included 3 months of daily sessions (1 indoor nutrition 
lesson, 4 outdoor physical activity lesions), followed by 3 months of biweekly sessions.  In 
addition, parents were invited to monthly meetings to learn about healthy eating and family meal 
planning.  To assess adherence to the intervention, participants took biweekly quizzes and wore 
heart rate monitors to ensure adequate exercise intensity.  The investigators attempted to 
individualize the intervention by modifying participant preferences and using preferred physical 
activities, in addition to providing all materials in both English and Spanish.  This study was 
rated fair without serious methodological flaws, but it did not report blinding of outcome 
assessors.         
 The study by Savoye et al was the largest of all the behavioral interventions and 
randomized 209 obese children to a family-based, intensive weight management intervention 
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(n=140), Bright Bodies, vs. traditional clinical counseling every 6 months as a control (n=69) and 
found a significant decrease in BMI.  The intervention arm was additionally randomized to 
receive a structured meal plan (n=35) or learn how to make better food choices (n=105), the 
former of which was discontinued because of a high drop-out rate (83%) at 6 months.  The 
participating children and their caregivers met together twice a week for 6 months, then twice a 
month for 6 months, to receive exercise and nutrition.  Behavioral modification sessions were 
also included, with children and caregivers separated, and concentrated on self-awareness, goal 
setting, stimulus control, coping skills training, cognitive behavior strategies and contingency 
management.  At 12 months, the weight management group had a significant decrease in BMI 
and percent body fat compared to the control group, as well as significant differences in fasting 
insulin and insulin sensitivity.  The study was only powered to allow for a 20% drop-out rate.  
This study was rated as poor due to the high overall drop-out rate (47%), high post-
randomization exclusions from discontinued arm (17%) and unknown blinding of outcome 
assessors.           
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Table 5. Summary of Behavioral Interventions 
Author, 
year 
Study 
design/ [N]/ 
Study 
Duration 
Intervention Outcome 
measure 
Results Quality 
Rating 
Ebbeling et 
al, 200651 
RCT 
 
103 
 
25 weeks 
Home 
delivery of 
non-caloric 
beverages/ 
instructed not 
to drink 
sugar-
sweetened 
beverages 
BMI 
(adjusted for 
age and 
gender) 
Intervention group 
BMI: 0.07 ± 0.14 kg/m2 
Control group 
BMI 0.21 ± 0.15 kg/m2 
 
Among upper baseline-
BMI tertile: 
Intervention BMI:  
–0.63 ± 0.23 kg/m2 
Control BMI: +0.12 ± 
0.26 kg/m2 
Net effect: BMI: –0.75 
± 0.34 kg/m2 
Good 
Germann et 
al, 200653 
Prospective 
cohort study 
 
150  
 
1 year 
FitMatters - 
includes 
cognitive-
behavioral 
therapy, 
nutritional 
counseling, 
exercise 
therapy, and 
medical 
management 
Body 
weight, 
BMI z-score 
Mean BMI z-score 
change: -0.05,  
SD = 1.41 
23% achieved clinically 
meaningful weight 
change, defined as  
-0.70 z-scores or better. 
Poor 
Johnston et 
al, 200754 
RCT 
 
60  
 
6 months 
Behavioral 
intervention  
I: self-help 
parent-guided 
manual (Trim 
Kids) vs. 
II: instructor-
led 
intervention 
with daily 
followed by 
biweekly 
sessions 
BMI z-score 
Intervention (II) 
Weight: – 1.75 ± 10.34 
kg 
BMI: – 1.16 ± 4.17 
kg/m2 
%BMI: – 2.81 ± 4.42 
Control (I) 
Weight: + 1.31 ± 1.53 
kg 
BMI: + 0.29 ± 0.51 
kg/m2 
%BMI: + 0.02 ± 1.69 
Fair 
Resnicow 
et al, 
200055 
Prospective 
cohort study 
 
Nutritional 
and physical 
activity 
BMI, % 
body fat, 
DXA, 
No significant 
difference when 
comparing high and 
Poor 
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57 
 
6 months 
intervention cholesterol, 
blood 
pressure and 
aerobic 
capacity 
low attendees.  
Raw change in BMI 
+0.7 in high attendees 
and +0.9 in low 
attendees 
Savoye et 
al, 200756 
RCT 
 
174 
 
1 year 
Bright Bodies 
Family-based 
intensive 
lifestyle 
intervention 
Body 
weight, 
BMI, % 
body fat 
Intervention 
Weight: 0.3kg (-1.4 to 
2.0) 
BMI: – 1.7 kg/m2 (-2.3 
to 
-1.1) 
Control 
Weight: 7.7kg (5.3 to 
10.0) 
BMI: 1.6 kg/m2 (0.8 to 
2.3) 
Poor 
Williamson  
et al, 
200658 
RCT 
 
57 
 
2 years 
Interactive 
behavioral 
internet 
program 
(intervention) 
vs. internet 
health 
education 
program 
(control) 
Body 
weight, 
BMI, body 
composition 
and weight 
loss 
behaviors 
Treatment:  
BMI +0.73 ± 0.66, 
%BMI – 0.004 ± 0.003 
Control:  
BMI +1.2 ± 0.65, 
%BMI – 0.001 ± 0.003 
Significant difference 
in % body fat at 6 mths, 
not 2 years.   
Poor 
 
 
Studies Examining Combination of Pharmacotherapy and Behavioral Interventions 
One randomized controlled trial49 and one secondary analysis50 of a previously published 
randomized controlled trial62 investigated the combination of pharmacotherapy with behavioral 
interventions in diverse populations.  Both studies used sibutramine (Meridia®) in conjunction 
with lifestyle changes to achieve expected optimal results in obese adolescents and found a 
significant decrease in BMI over placebo.  The study by Berkowitz was the largest of all the 
included articles, enrolling 498 participants from 33 outpatient centers throughout the United 
States.  The behavioral intervention in this study was site-specific, varying across study 
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participants, whereas the behavioral program used in Budd et al was the same family-based 
weight loss program.  Both studies used sibutramine 10 mg daily, although one study49 allowed 
for an increase to 15 mg if BMI was not reduced by 10% in 6 months, which occurred in 47.9% 
of participants.  The trials also measured adverse events to evaluate the safety of sibutramine use 
in adolescents.     
The 2006 study by Berkowitz et al looked at severely obese participants with a body 
mass index of at least two units more than the 95th percentile for age and sex.  The randomized 
controlled trial was conducted over one year, with a 3:1 randomization to site-specific behavioral 
therapy and sibutramine vs. placebo.  All participants received behavioral treatment instruction 
that was designed by the specific center.  These instructions included patient-centered lifestyle 
modifications, such as healthy eating and physical activity counseling, self monitoring, stress 
management, stimulus control, problem solving, contingency management, cognitive 
restructuring and social support.  The behavioral therapy and sibutramine group significantly 
decreased BMI when compared to behavioral therapy and placebo, as well as produced larger 
improvements in percent weight loss, waist circumference, triglyceride levels, high-density 
lipoprotein (HDL) cholesterol levels, insulin levels and insulin sensitivity.  The study only 
measured BMI and did not include any other measure, such as percent BMI or BMI z-score.  
Children included in the study were ages 12-16 and could still be growing, which would make 
BMI measurements less useful.  However, the use of waist circumference is useful in assessing 
adiposity loss, especially visceral adiposity.  The overall completion rate was only 72%, although 
the estimated sample size allowed for a 50% drop-out rate with the expected treatment effects.  
The placebo group had a greater drop-out rate than the sibutramine group (62% vs. 76%).  Due 
to the differential loss-to-follow-up, this article was rated fair.  However, the rate of tachycardia 
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with sibutramine was significantly more than in the placebo group and adverse events led to 
withdrawal in 6.3% of the treatment group and 5.4% of the placebo group.              
 Budd et al performed a subset analysis (n = 79 out of N = 82 in the overall RCT) of a 
randomized controlled trial published elsewhere,62 in which 34 African American and 45 
Caucasian children with a mean age of 14.1 years were randomized to a family-based behavioral 
intervention and sibutramine or family-based behavioral intervention and placebo.  The original 
article by Berkowitz et al (2003), which assessed behavioral therapy and sibutramine vs. placebo 
in a diverse sample, assessed change in percent BMI and BMI z-scores between the treatment 
and control groups for the first 6 months, and then transitioned to open-label treatment of 
sibutramine for the entire sample.  Adherence to lifestyle program and hunger was measured, as 
well as blood pressure and pulse for safety measure.  Unlike the other pharmacotherapy trials, 
this study enrolled children who were overweight or obese, with a body mass index of at least the 
85th percentile.  The sibutramine group significantly lost a greater percentage BMI than the 
placebo group and the difference in BMI z-score was statistically significant.  During the 12 
months, nineteen participants experienced elevations in blood pressure and pulse significant 
enough to warrant reductions, five of which discontinued treatment.  Two participants 
experienced ventricular premature complexes, although one case was not thought to be 
medication-related. However, this study does raise safety concerns of sibutramine use in 
adolescents.  This original article by Berkowitz et al (2003) was rated good.  
Racial and ethnic groups were not evenly distributed in the original analysis, so Budd et 
al compared weight loss and metabolic risk factors in African-American and Caucasian 
adolescents as a secondary analysis.  No differences in initial BMI or BMI z-score were found 
comparing African-American and Caucasian adolescents, but larger waist circumferences, higher 
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triglycerides and higher cholesterol levels were found in the Caucasian group at baseline.  
Retention did not differ between the two racial groups.  In Caucasians, the sibutramine group 
experienced a larger percent BMI change at 6 months than the African-American sibutramine 
group.  The percent BMI change in the African American group was not statistically significant 
between sibutramine and placebo groups, but investigators thought this could have been due to 
the smaller sample size of African Americans.  The percent change in BMI was not significantly 
different between the Caucasian and African American placebo and sibutramine groups.  Both 
racial groups had significant decreases in metabolic risk factors.  However, these results should 
be interpreted cautiously since the original study was not powered for subset analysis, resulting 
in a fair rating.  Overall, the 14% of patients discontinued treatment due to adverse events.  
 
Table 6. Summary of Pharmacotherapy/Behavioral Interventions 
Author, year Study 
design/ [N]/ 
Study 
Duration 
Intervention Outcome 
measure 
Results Quality 
Rating 
Berkowitz  
et al, 200649 
RCT 
 
498 
 
1 year 
Behavior 
therapy + 
sibutramine 
vs. 
behavioral 
therapy + 
placebo 
BMI, Body 
weight, waist 
circum., 
fasting lipid 
and glycemic 
variables, 
safety, 
tolerability 
Sibutramine 
Weight: –6.5kg ± 
0.3kg 
BMI: –2.9 kg/m2 
[95% CI –3.5 to –2.2 
kg/m2] 
 
Placebo 
Weight: +1.9 ± 0.56 
kg   
BMI: –0.3 kg/m2 
[95% CI –0.4 to –0.2 
kg/m2] 
 
Difference, BMI:  
–2.6 kg/m2 [95% CI  
–3.1 to –2.0 kg/m2]  
P < 0.001 
Fair 
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Budd et al, 
2007 50 
RCT 
(secondary 
analysis) 
 
82 
 
6 months 
Family-
based 
behavioral 
therapy + 
placebo vs. 
Family-
based 
behavioral 
therapy + 
sibutramine 
Body 
weight, BMI, 
% BMI, 
fasting 
glucose, 
insulin, 
insulin 
resistance, 
lipid levels 
Overall* 
Mean change %BMI: 
BT† + Sibutramine:  
– 8.5 (SD 6.8) 
BT + Placebo: – 4.0 
(SD 5.4) 
Mean change in BMI 
z-score: 
BT + Sibutramine:  
– 0.2 (0.2) 
BT + Placebo: – 0.1 
(0.1) 
 
Sibutramine 
African-Americans 
Weight: – 6.9 ± 6.2 
kg 
BMI: – 2.9 ± 2.7 
kg/m2 
Caucasians 
Weight: – 9.0 ± 6.4 
kg 
BMI: – 3.6 ± 2.5 
kg/m2 
Placebo 
African-Americans 
Weight: – 3.4 ± 6.8 
kg 
BMI: – 1.4 ± 2.0 
kg/m2 
Caucasians 
Weight: – 3.0 ± 5.9 
kg 
BMI: – 1.6 ± 2.1 
kg/m2 
Good 
(original 
article)/ 
Fair 
* Results from original article 
† Behavior therapy 
 
 
General Efficacy 
 In general, five studies49, 50, 54, 56, 57 were shown to be effective in reducing body mass 
index, percent BMI or BMI z-score, while four studies52, 53, 55, 58 were ineffective in reducing 
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these measures.  One study51 was shown to be effective only in those children who were in the 
upper baseline-BMI tertile, but not for the sample as a whole.  However, this was also the only 
study that included children who were not overweight or obese.  The overall strength of the 
evidence for each intervention is summarized in Tables 7, 8 and 9.     
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Overall Strength of Evidence 
Table 7. Evidence Profile for Pharmacotherapy options for treatment of childhood obesity 
No. of 
studies/ 
Patients 
Study 
Design 
Study Quality Consistency Comments Summary of 
findings 
Overall 
Grade of 
Evidence 
1 / 46 
patients 
RCT Fair N/A None No 
significant 
difference 
Low 
1 / 28 
patients 
RCT Good N/A Small sample 
size, limited 
external validity 
Metformin 
showed 
benefit over 
placebo 
Moderate 
 
 
Table 8. Evidence Profile for Behavioral treatments of childhood obesity 
Evidence profile: Comparative efficacy of behavioral interventions 
No. of 
studies/ 
Patients 
Study 
Design 
Study  
Quality 
Consistency Comments Summary 
of 
findings 
Overall 
Grade of 
Evidence 
Decrease in Sugar-Sweetened Beverages vs. Maintain current habits 
Outcome: BMI 
1 / 103 
patients 
RCT Good N/A Included non-
overweight 
children 
No 
overall 
difference  
Moderate 
Internet-based interactive intervention vs. internet-based education 
Outcome: BMI, %BMI 
1 / 57 
patients 
RCT Poor / serious 
methodological 
problems 
N/A Slight benefit 
in percent 
body fat at 6 
months  
No 
difference 
in BMI at 
6 or 12 
months 
Low 
Intensive lifestyle intervention 
Outcome: BMI, BMI z-score 
4/ 476 
patients  
2 obs. 
studies, 
2 
RCTs 
2 poor quality 
with serious 
methodological 
problems and 2 
fair quality 
Some 
inconsistencies
None 2 RCTs 
showed 
significant 
difference  
Low 
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Table 9. Evidence Profile for Combined Behavioral and Pharmacotherapy Treatments of 
Childhood Obesity 
Evidence profile: Comparative efficacy of combined behavioral/pharmacotherapy interventions 
No. of 
studies/ 
Patients 
Study 
Design 
Study  
Quality 
Consistency Comments Summary 
of findings 
Overall 
Grade of 
Evidence 
Behavioral intervention + sibutamine vs. placebo 
Outcome: BMI, %BMI, BMI z-score 
2 / 580 
patients 
RCTs Fair No 
inconsistencies 
None Significant 
decrease in 
BMI over 
placebo 
Moderate 
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DISCUSSION 
 Childhood and adolescent obesity is an epidemic, disproportionately affecting minority 
populations and exposing youth to irreversible cardiovascular complications.  Much research has 
been done to identify interventions that are effective in treating obesity, but results of this review 
show that there is deficient evidence and few high quality studies on pediatric obesity 
interventions in minority populations.  Several studies were not considered for this review 
because of lacking minority representation, a critical aspect in current obesity research 
considering the existing disparities.    
 Of the included studies, many were limited due to small sample size or high attrition 
rates.  Although decreased compliance and drop-outs might be expected in intensive behavioral 
interventions and increase external validity of these studies by reflecting reality, the internal 
validity is still limited and the efficacy of the intervention unclear.  Most studies had a short 
duration, with few interventions evaluating the effects beyond six months. The one study that 
had a follow-up of two years showed no treatment difference.    
 All pharmacotherapy studies offered some type of lifestyle counseling, whether or not it 
was included in the measures.  These studies showed a beneficial effect of sibutramine or 
metformin over placebo, but the external validity is limited.  Children who would be offered 
pharmacotherapy would most likely be severely obese and be referred to a specialty clinic, since 
primary care physicians may not be comfortable prescribing experimental medications.  These 
individuals would have to be involved in the health care system to receive this opportunity.  
Even with a prescription or a referral to a specialty clinic, weight-loss medications like 
sibutramine are expensive and often not covered by insurance.70 
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 The use of pharmacotherapy in children should also be carefully weighed against possible 
harms.  The Food and Drug Administration has approved sibutramine in adolescents of 16 years 
or older, and use under the age of 16 is considered experimental.71  Although pharmacotherapy 
in conjunction with lifestyle changes has shown a beneficial effect over lifestyle changes alone, 
the effect size is modest.  Significant adverse events were documented in all pharmacologic 
treatments, some leading to discontinuation.  Individuals for whom pharmacologic treatment is 
appropriate should be under careful observation and monitoring.  Lifestyle changes should 
remain first-line treatment, reserving medication use for individuals who have failed behavioral 
interventions or are at high risk for metabolic cormorbidities and cardiovascular complications.72 
 
Limitations 
 Although this review was done systematically, it still has specific limitations.  One 
person conducted the literature search, article selection and grading of the evidence.  In order to 
make up for this limitation, the process was written with full disclosure so that the reader can 
make his or her own assessment should it differ from the author.  Secondly, the review 
concentrated on diverse populations or specific minority groups to assess interventions in the 
group that disproportionately carries the burden.  Generalizing among groups is a potential 
limitation of the studies themselves that contributed to the lack of strength of the evidence.  
Specific differences between Hispanics and African Americans or between two children of the 
same race may exist, such as socioeconomic status, education and family history, which interfere 
with a child’s ability to lose weight.  The articles attempted to control for these factors but other 
unknown confounders may still be present.   
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Included studies may be limited due to selection bias.  Many studies relied on recruitment 
for study enrollment.  Participants who enroll could be different from those who decide not to 
enroll in a study.  In addition, they may be more motivated to lose weight in general, which 
could lessen the treatment effect if both intervention and control groups were more likely to lose 
weight.  On the other hand, studies could suffer from high drop-out or non-compliance rates if 
participants were not as willing to be involved in the study.   
 
Future Research 
 As this review highlighted, more research of diverse populations is needed to assess 
interventions in all children.  The vast amount of literature of pediatric obesity is impressive, but 
only ten articles could be found that included a sufficient number of minorities.  Many of the 
studies were limited by small sample sizes, short-term follow-up or large drop-out rates.  Large 
randomized controlled trials that include children from all backgrounds should be conducted in 
each type of intervention, especially behavioral interventions. The research community should 
evaluate a standard intervention in different populations- varied racial/ ethnic groups, rural or 
urban, low or high-income, less educated, etc- to gain information on generalizability.  Intensive 
interventions may be difficult to maintain participation and can have high drop-out rates.  
Perhaps assessing the readiness of pediatric patients to change and offering these interventions to 
highly motivated individuals could increase a study’s validity and efficacy, although limit 
external validity.  In addition, long-term follow-up is critical to assess maintenance of weight 
loss and resulting benefits. 
 Important points for future research not addressed in this review are the effects of 
interventions in preventing or delaying the metabolic effects of insulin resistance and Type II 
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diabetes, in addition to its effects on body composition.  Some studies have analyzed the 
metabolic effects, especially of pharmacotherapy, and perhaps this could be the subject of future 
studies in minority populations or a future systematic review.  
 Although cost-effectiveness was not addressed in this review, its role in future research is 
significant considering the lifelong health consequences and cardiovascular risks initiated by 
childhood obesity are considered an epidemic problem and public health emergency.  These 
studies would be difficult to perform, but considering the amount of resources the health care 
system puts into cardiovascular disease, evidence of effective obesity interventions in children 
could possibly prevent or delay complications and prove cost-effective.  An article on short-term 
cost-effectiveness in the method of delivering an intervention has been published,73 but does not 
take into account the cost of lasting health consequences.  Another study estimated costs about 
$200 a year for overweight or obese children, which could cover 4 visits to a dietician per year.74  
To receive any short-term return of investment, all costs from the child’s overweight or obesity 
would have to be eliminated.  However, considering the lifelong costs of obesity, long-term cost-
effectiveness is possible with childhood obesity interventions.74  Although studies on cost-
effectiveness are helpful, the quality of childhood obesity interventions should not be based on 
financial incentive, but rather efficient weight loss and an increase in quality of life and 
longevity.74     
Future interventions should be designed with specific ethnic or cultural considerations 
that will not exclude children of different backgrounds.  All children should have equal 
opportunity to obesity treatments.  Segregation of interventions by population or by racial/ethnic 
group may prevent exposing the root causes of obesity and addressing these issues, even if an 
intervention may be more effective in certain populations.  Although prevention was not 
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addressed in this systematic review, additional research on the prevention of childhood obesity 
and potential risk factors to target early intervention are needed. 
 The obesity epidemic in children and adolescents has left pediatric providers searching 
for effective treatments for their patients.  Much of the literature does not provide answers as few 
studies have taken place in the primary care setting.75  Outside of community- or family-based 
interventions, clinical interventions tend to recruit patients from endocrine or specialty obesity 
clinics.  Although these patients are in critical need of intervention, these results are not 
generalizable to the general population, in addition to limiting interventions to those children 
without access to the health care system and referrals to specialty clinics.  No one intervention is 
likely to solve the problem of pediatric obesity, but the diverse backgrounds of afflicted children, 
as well as disparities across racial and ethnic groups, warrant a combined public health approach 
that targets the individual, the family and the community.       
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Appendix A. Quality Assessment Methods  
 
Internal Validity (criteria used by U.S. Preventive Services Task Force) 
 
Controlled Trials:  
• Comparable groups  
o Adequate randomization (sequence generation, computer-generated, etc) 
o Allocation concealment (concealed randomization, centralized randomization, 
etc) 
o Groups similar at baseline, equally at risk 
• Eligibility criteria specified 
• Maintenance of comparable groups 
o Attrition 
o Crossovers 
o Adherence 
o Contamination 
• Loss-to-follow-up 
o Overall high loss-to-follow-up 
o Differential loss-to-follow-up 
• Measurements 
o Equal, reliable, valid 
o Blinding of outcome assessors to treatment allocation 
• Clear definition of intervention 
• Important outcomes considered 
• Analysis 
o Intention-to-treat 
o Post-randomization exclusions 
 
Observational Studies: (Deeks, et al) 
• Same source population for both groups? 
• Same risk of developing outcome at baseline (i.e. obesity)? 
• Subjects recruited over same time period? 
• Obvious selection bias? 
• Ascertainment methods adequate and equally applied? 
• Attempt to blind outcome assessors? 
• Equal follow-up time period? 
• Overall attrition high (> 20%)? 
• Differential attrition high (> 15%)? 
• Attempt to control for potential confounders in statistical analysis or different lengths of 
follow-up? 
• Adequate length of follow-up? 
 
External Validity 
 
• Similarity of study population to general population deserving of intervention? 
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• Recruited patients? 
• Exclusion criteria?   
• Funding source and role of funder? 
• Did control group receive standard of care? 
• Length of follow-up? 
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APPENDIX B. EVIDENCE TABLES 
 
STUDY Author: Berkowitz et al49 
Year: 2006 
FUNDING: Abbott Pharmaceuticals (makers of sibutramine) 
RESEARCH 
OBJECTIVE: 
To see if sibutramine increased weight loss more than placebo 
in obese adolescents who were also receiving behavioral 
therapy.   
METHODS: 12 month intervention with follow up at month 6 and 12. 
Weekly visits for first 2 weeks, bimonthly visits until week 12, 
and month visits after. 
Participant, investigators and statisticians blinded.   
PARTICIPANTS: N = 498, ages 12 – 16 years, BMI at least 2 units greater than 
95th percentile based on age and sex.   
Subjects from 33 U.S. outpatient centers 
3:1 randomization, n= 368 to sibutramine, n= 130 to placebo 
INTERVENTION: Instruction in center-specific behavioral program (nutritional 
counseling, self-monitoring of eating habits and physical 
activity, stress management, stimulus control, contingency 
management, cognitive restructuring, social support, dietary and 
physical activity counseling) + randomization to 10mg 
sibutramine or placebo.  If subject did not lose more than 10% 
of initial BMI by month 6, then sibutramine or placebo was 
increased to 15mg.       
OUTCOME 
ASSESSMENT: 
Primary: change from baseline BMI 
Secondary: percentage change in BMI, proportion of patients 
achieving BMI reductions of 5% or more or 10% or more, 
absolute and percentage changes in body weight and lipid and 
glycemic variables, change in waist circumference. 
Safety assessments: reported adverse events, changes in blood 
pressure and pulse rate, electrocardiographic variables.  
Also measured growth (height) and sexual maturation (Tanner 
staging). 
RESULTS: The estimated mean treatment group difference (after 12 
months) for change in BMI was – 2.9 kg/m2 [95% CI, -3.5 to -
2.2 kg/m2] and body weight – 8.4 kg [95% CI, -9.7 to -7.2 kg]. 
P < 0.001 for both.  Sibutramine group also had significant 
improvements in triglyceride levels, HDL levels, insulin levels 
and insulin sensitivity (P < 0.001).  Tachycardia was greater for 
sibutramine (12.5% vs. 6.2% placebo).    
ADVERSE 
EVENTS: 
Tachycardia more common in sibutramine group than placebo. 
Other AE’s (with difference in rates of more than 1 percentage 
pt) were dry mouth, constipation, dizziness. Hypertension 
caused withdrawal of 5 treatment group participants (0 
placebo). 10/368 sibutramine and 1/130 placebo reported 
serious AE’s, including nausea, vomiting   
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ADHERENCE/ 
COMPLIANCE: 
Assessed by pill count. 89.1% mean adherence in sibutramine 
group and 83.9% in placebo group.  
ANALYSIS: ITT:* modified (defined as all participants who received at least 
1 dose of study medication and recorded at least 1 post-baseline 
BMI).  Last-observation-carried-forward with mixed linear 
effects model. 
Post-randomization exclusions: None reported 
ADEQUATE 
RANDOMIZATION:
Yes 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Yes 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Yes 
ATTRITION: 
 
Overall: 72% 
Treatment-specific: 76% in sibutramine group vs. 62% in placebo 
group (P = 0.001)  
NOTES AE’s not pre-specified 
QUALITY RATING Fair 
*ITT = intention-to-treat 
 
 
 
STUDY Author: Berkowitz et al, 200362 (original article)  
               Budd et al50 (secondary analysis) 
Year: 2007 
FUNDING: Knoll Pharmaceuticals/ Abbott Laboratories 
RESEARCH 
OBJECTIVE: 
To examine and compare changes in weight loss and 
cardiometabolic risk factors in African American and Caucasian 
adolescents with familial-based behavioral therapy + 
sibutramine or placebo.   
METHODS:  
PARTICIPANTS: N = 82 randomized; 79 in secondary analysis; ages 13 – 17 
years; BMI ≥ 85th percentile (mean BMI 37.8 kg/m2); from 
March 1999 to August 2002 at university-based clinic. 
INTERVENTION: 6 month intervention of sibutramine + family-based behavioral 
therapy vs. placebo + same behavioral therapy, then open-label 
sibutramine treatment for all participants until month 12.   
OUTCOME 
ASSESSMENT: 
Primary: weight, BMI, BMI z-scores, % change in BMI 
Secondary: blood pressure, pulse, hunger 
 Sibutramine + BT * Placebo + BT 
Weight – 7.8 kg (SD 6.3) – 3.2 kg (SD 6.1)  p=0.001
% BMI – 8.5% (SD 6.8%) – 4.0% (SD 5.4)   p=0.001 
RESULTS: 
BMI z-score – 0.2 (0.2) – 0.1 (0.1)            p=0.003 
ADVERSE Pre-defined: Elevations in BP, pulse 
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EVENTS: 1 patient with ventricular premature complexes (VPCs) 
(continued 6 months after sibutramine discontinued, thought 
benign 
1 patient with VPCs at 9 months, 3 weeks after sibutramine 
discontinued, gone at 12 months.  Both asymptomatic. 
During 12 months, sibutramine reduced to 10mg in 16 subjects, 
5 mg in 7 additional subjects, and discontinued in10 participants 
19/43 experienced significant elevations of BP and pulse that 
led to reductions, and discontinuation in 5 patients.  
ADHERENCE/ 
COMPLIANCE: 
Pill count: treatment group used 79.1% of prescribed pills and 
control group used 78.3% of prescribed pills.  
ANALYSIS: ITT: Yes 
Post-randomization exclusions: No  
ADEQUATE 
RANDOMIZATION:
Randomization scheme not described, small baseline 
differences in gender and race 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Yes 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Yes 
ATTRITION: 
 
At 6 months: 8 (5 placebo, 3 treatment) 
At 12 months: 20 (10 placebo, 10 treatment) 
NOTES: Statistical difference in BMI z-score, but maybe not clinically 
meaningful.  Absolute difference small. 
BMI decreased additional 2.4% in control group once switched 
to open-label treatment from months 7-12. 
QUALITY RATING Good (original article) / Fair (Budd) 
* Behavior Therapy 
 
 
 
STUDY Author: Ebbeling et al51 
Year: 2006 
FUNDING: Grants, National Institute of Diabetes and Digestive Kidney 
Diseases, Charles H. Hood Foundation and National Institutes 
of Health 
RESEARCH 
OBJECTIVE: 
To examine the effects of decreasing sugar-sweetened 
beverages on body weight   
METHODS: Blinded randomization, stratified by gender and BMI. 
Telephone contact in first week and then monthly to discuss 
beverage consumption and provide motivational counseling.  
Provided in-person training to estimate food/beverage 
consumption and describe physical activity intensity.  Baseline 
BMI considered an effect modifier (p = 0.016).   
PARTICIPANTS: N = 103 randomized (47 males, 56 females), ages 13 – 18 years, 
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who reported consuming at least 1 serving of sugary beverage 
per day.  Excluded those who were currently dieting, cigarette 
smokers or BMI less than 25th percentile.     
INTERVENTION: 25 weeks of home delivery of non-caloric beverages of choice 
based on household size and instructions not to consume sugar-
sweetened beverages.  Control group asked to continue usual 
beverage consumption habits.  
OUTCOME 
ASSESSMENT: 
Primary end points: change in body mass index (BMI) 
Primary process measure: change in consumption of sugar-
sweetened beverages  
RESULTS: Intervention group: consumption of sugary beverages decreased 
by 82%, change in BMI was 0.07 ± 0.14 kg/m2. 
Control group: 0.21 ± 0.15 kg/m2 
Net difference: - 0.14 ± 0.21 kg/m2 (not significant) 
Among upper baseline-BMI tertile, BMI change in intervention 
was -0.63 ± 0.23 kg/m2 and in control +0.12 ± 0.26 kg/m2. 
statistically significant (p= 0.03). 
Greater effect among subjects who drank more sugar beverages 
at baseline.  
No change in physical activity, television viewing or total 
media time in either group.   
ADVERSE 
EVENTS: 
None. 
ADHERENCE/ 
COMPLIANCE: 
Assessed by phone interview, self-report, questionnaire.  
83% completed interviews in intervention group.  
ANALYSIS: Intention-to-treat: Yes 
ADEQUATE 
RANDOMIZATION:
Yes 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
No/ Not possible 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Yes (interviewers blinded) 
ATTRITION: 100% completion rate 
NOTES: Limitations: relatively small sample size, short intervention 
period, reliance on self-report, no pubertal status staging (but 
randomized). 
QUALITY RATING Good 
 
 
 
 
STUDY Author: García-Morales et al52 
Year: 2006 
FUNDING: Not reported 
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RESEARCH 
OBJECTIVE: 
Assess efficacy and safety of sibutramine in obese Mexican 
adolescents 
METHODS: Run-in period prior to randomization. 
PARTICIPANTS: N = 46 (n = 23 sibutramine, n = 23 placebo), ages 14-18 years, 
BMI > 95th percentile 
INTERVENTION: 6 months of 10 mg sibutramine daily vs. placebo daily, in 
addition to individualized recommendations on healthy diet and 
physical activity.  
OUTCOME 
ASSESSMENT: 
Primary end points: change in body weight, BMI, % BMI 
Secondary end points: waist circumference 
RESULTS: Sibutramine group: Net weight loss of 7.3 kg [95% CI, 4.6-9.9], 
waist circumference loss of 8.0 cm [95% CI, 4.7-11.3], %BMI 
loss of 9.2% [95% CI, 6.9-11.6]. 
Placebo group: Net weight loss of 4.3 kg [95% CI, 1.7-6.9], 
waiste circumference loss of 3.8 cm [95% CI, 0.7-7.0], %BMI 
loss of 5.2% [95% CI, 2.4-7.9] 
Intragroup comparisons, P < 0.05; intergroup comparisons, P > 
0.05.   
ADVERSE 
EVENTS: 
Sibutramine group: 1 with increased blood pressure, 3 with 
increased heart rate; Placebo group: 2 with increased blood 
pressure, 2 with increased heart rate. All subsided within a week 
and did not lead to withdrawal.   
Mild adverse events: Sibutramine group had 3 patients with 
headache, dry mouth, headache with nausea and headache with 
weakness and paleness (p>0.05); Placebo group had 3 patients 
with 2 cases of headache, 1 case of headache with somnolence 
and 1 case of headache with dry mouth (p>0.05).   
ADHERENCE/ 
COMPLIANCE: 
Pill count 
Physical activity successful with completion of 3 days of at 
least 30 min of exercise.  
90-100% compliance rate 
ANALYSIS: ITT: modified (does not include the data from 5 early drop-out 
patients).  
Last-observation-carried-forward also reported. 
Post-randomization exclusions: yes (5 patients who dropped out 
before 1st month of treatment).  
ADEQUATE 
RANDOMIZATION:
Yes 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Yes 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Yes 
ATTRITION: Overall attrition: 6 (13%) 
2 drop-outs in sibutramine group, 4 drop-outs in placebo group  
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NOTES:  
QUALITY RATING Fair 
 
 
 
 
STUDY Author: Germann et al53 
Year: 2006 
FUNDING: Galter Foundation, Foundation for Health Enhancement, 
Federick E. and Ida M. Hummel Foundation, Max Goldenberg 
Foundation 
RESEARCH 
OBJECTIVE: 
To assess the effectiveness of the FitMatters treatment program 
in morbidly obese, low-income, minority adolescents  
METHODS: Analysis to determine differences between groups of 
participants on individual and family measures of behavioral/ 
emotional stability, pretreatment weight control and exercise 
behaviors, process measures, demographic variables, 
discriminated between “successful” and “less successful” 
groups to assess differences. Secondary analysis compared 
weight gain before and after participating in treatment, by using 
a comparison group (whose records were available). 
PARTICIPANTS: N = 150 randomized (76 male, 74 female); follow-up data on 83 
participants; age ≥ 8 years; BMI ≥ 95th percentile   
INTERVENTION: Behavioral intervention, FitMatters program: cognitive-
behavioral therapy, nutritional education, medical monitoring 
and structured exercise training 
Average follow-up: 23 months 
OUTCOME 
ASSESSMENT: 
Primary outcome: BMI z-score 
Process measures: child and parental self-monitoring 
Additional measures: differences between “successful” and 
“less successful” groups in individual and family measures of 
behavioral/ emotional stability, pretreatment weight control and 
exercise behaviors, process measures, demographic variables, 
and compared weight gain before and after participating 
program with comparison group.  
RESULTS: Mean BMI z-score change: -0.05, SD = 1.41 
23% achieved clinically meaningful weight change, defined as  
-0.70 z-scores or better. 
ADVERSE 
EVENTS: 
None reported 
ADHERENCE/ 
COMPLIANCE: 
83 (55.3%) participated in follow-up 
Compliance in program unclear 
ANALYSIS: ANOVA 
ADEQUATE 
RANDOMIZATION:
Not applicable 
ADEQUATE Not applicable 
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ALLOCATION 
CONCEALMENT: 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Not reported 
ATTRITION: 67 (44.7%)  
NOTES: Looked at differences that might correlate with success 
QUALITY RATING Poor 
 
 
 
 
STUDY Author: Johnston et al54 
Year: 2007 
FUNDING: US Department of Agriculture grant 
RESEARCH 
OBJECTIVE: 
Evaluate an intensive healthy lifestyle intervention for weight 
loss in overweight Mexican-American children compared to a 
self-help program. 
METHODS: Follow-up at 3 and 6 months 
PARTICIPANTS: N = 60 (33 boys); ages 10-14; ≥ 85th percentile in BMI for age 
and sex; randomized 2:1 (40 treatment, 20 control) 
INTERVENTION: 12 weeks of instructor-led intervention with daily sessions 
during school followed by 12 weeks of biweekly sessions vs. 12 
week self-help parent-guided manual (Trim Kids).   
OUTCOME 
ASSESSMENT: 
Primary: BMI, %BMI, BMI z-score 
Secondary: cholesterol, blood pressure, insulin 
RESULTS: zBMI change: F = 12.74, P < 0.001 
Intervention (II): Weight: – 1.75 ± 10.34 kg, BMI: – 1.16 ± 4.17 
kg/m2, %BMI: – 2.81 ± 4.42 
Control (I): Weight: + 1.31 ± 1.53 kg, BMI: + 0.29 ± 0.51 
kg/m2, %BMI: + 0.02 ± 1.69 
ADVERSE 
EVENTS: 
None reported 
ADHERENCE/ 
COMPLIANCE: 
Biweekly quizzes to test if children were learning the material; 
point system/rewards for participation 
ANALYSIS: ITT: Yes 
Post-randomization exclusions? No 
ADEQUATE 
RANDOMIZATION:
Yes 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Not possible 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Not reported  
ATTRITION: 3 (95% completion rate) 
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NOTES: Minimal exclusion criteria among overweight Mexican-
American children. 
Included cultural considerations in treatment 
QUALITY RATING Fair 
 
 
 
 
STUDY Author: Resnicow et al76 
Year: 2000 
FUNDING: CDC 
RESEARCH 
OBJECTIVE: 
Evaluate a behavioral intervention in overweight, low-income, 
African-American adolescent females 
METHODS:  
PARTICIPANTS: Recruited from public housing development ; N = 57; ages 11-
17; BMI ≥ 85th percentile for age and sex;  
INTERVENTION: Behavioral intervention based on social cognitive theory that 
focused on increasing fruit and vegetable uptake, decreasing fat 
intake, decreasing fast food intake, decreasing television 
viewing and increasing physical activity. 
OUTCOME 
ASSESSMENT: 
Physiologic measures: BMI, % body fat, DXA, cholesterol, 
blood pressure and aerobic capacity 
Physical activity and sedentary behaviors reported based on 1 
week recall 
Psychosocial measures: self-esteem, preoccupation with weight 
and food, social support, self-efficacy, health knowledge and 
perceived weight 
Compared high (> 50% of sessions) and low attendees (groups 
differed in baseline cholesterol and blood pressure) 
RESULTS:  No significant difference between high and low attendees for 
any physical measure (slight trend favoring high attendees); 
high attendees had significantly greater nutrition knowledge 
scores, reported significantly more low-fat intake, were more 
likely to perceive positive dietary changes, reported more social 
support.   
Based on raw change values, both groups showed an increase in 
body weight and BMI. 
ADVERSE 
EVENTS: 
None reported.  
ADHERENCE/ 
COMPLIANCE: 
On average, girls attended 43% of sessions 
Point system/ rewards to encourage participation 
ANALYSIS: Analysis of variance 
ADEQUATE 
RANDOMIZATION:
Not applicable 
ADEQUATE 
ALLOCATION 
Not applicable 
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CONCEALMENT: 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Not reported 
ATTRITION: Drop-out rate 45% 
NOTES: Intervention based on focus group data 
QUALITY RATING Poor 
 
 
 
 
STUDY Author: Savoye et al56 
Year: 2007 
FUNDING: NIH 
RESEARCH 
OBJECTIVE: 
Compare effects of weight management intervention (Bright 
Bodies) on body composition and metabolic parameters in 
overweight children over control 
METHODS:  
PARTICIPANTS: N = 209; ages 8 – 16; BMI > 95th percentile 
INTERVENTION: Control group had traditional clinical weight management 
counseling every 6 months vs. intervention group had intensive 
family-based program (biweekly the first 6 months, bimonthly 
after) including exercise, nutrition and behavioral modification 
for participants and caregivers.   
Weight management group with structured meal plan approach 
was discontinued due to high drop out rate (83% drop-out rate 
at 6 months) 
OUTCOME 
ASSESSMENT: 
Weight, BMI, body fat, insulin resistance at 6 and 12 months 
RESULTS: Treatment effect: 
Weight: 7.6 kg at 6 months, 7.4 kg at 12 months (p < 0.001) 
BMI: 3.1 kg/m2 at 6 mths, 3.3 kg/m2 at 12 mths (p < 0.001) 
% body fat: 5.2 at 6 mths, 6.0 at 12 mths (p < 0.001) 
Change in BMI (kg/m2): intervention -2.1 (95% CI -2.6 to -1.5) 
at 6 mths, -1.7 (95% CI -2.3 to -1.1) at 12 mths vs. control +1.1 
(95% CI 0.4 to 1.8) at 6 mths, +1.6 (95% CI 0.8 to 2.3) at 12 
mths  
Significant difference in fasting insulin (treatment -1.51 vs. 
control +0.33 at 6 mths, treatment -1.52 vs. control +0.90 at 12 
mths). 
ADVERSE 
EVENTS: 
None reported 
ADHERENCE/ 
COMPLIANCE: 
Heart rate monitor worn during exercise to ensure adequate 
intensity 
Attendance not reported 
ANALYSIS: ITT: yes 
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Post-randomization exclusions? Study arm discontinued 
ADEQUATE 
RANDOMIZATION:
Yes 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Not possible 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Not reported 
ATTRITION: 60% completed 6 months, 53% completed 12 months 
(powered to allow for 20% drop-out) 
Study arm discontinued due to 83% drop-out at 6 mths 
NOTES: Limited to English-speaking 
No statistical significance in drop-out rates among ethnic 
groups (minority participants with somewhat greater retention 
than white participants) 
QUALITY RATING Poor 
 
 
 
 
STUDY Author: Srinivasan et al57 
Year: 2006 
FUNDING: National Health Medical Research Scholarship, Diabetes 
Australia Research Trust grant 
RESEARCH 
OBJECTIVE: 
Examine the effects of metformin on body composition and 
insulin sensitivity in obese pediatric patients 
METHODS: 2 weeks wash-out, cross-over design 
PARTICIPANTS: N = 28 (13 males); ages 9-18 years; 64% from other 
racial/ethnic background in Australia, included more Pacific 
Islanders, Indians;  clinical suspicion of insulin resistance; 13 
participants to metformin first, then placebo; 15 participants to 
placebo then metformin. 
INTERVENTION: Metformin 1 g twice daily vs. placebo for 6 months (cross-over 
design) 
OUTCOME 
ASSESSMENT: 
Weight, height, BMI, BMI z-score, waist circumference, 
glucose tolerance test, blood pressure, DXA imaging, 
abdominal MRI 
Safety outcomes: liver function tests, serum creatinine, serum 
lactate levels 
RESULTS:  Metformin treatment effect: Weight -4.35 kg (p = 0.02); 
Weight z-score -0.09 kg (p=0.009); BMI -1.26 kg/m2 (p = 
0.002); BMI z-score -0.12 kg/m2 (p = 0.005) 
Improvements in fasting serum glucose and insulin, but not 
insulin sensitivity. 
ADVERSE Nausea (2 participants, age 9, unable to tolerate 1 g metformin, 
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EVENTS: but tolerated 750mg twice daily after slow increments) 
No difference in LFTs, serum creatinine or lactate levels. 
ADHERENCE/ 
COMPLIANCE: 
Pill count every 3 months 
Metformin median adherence 78% (15-99%); placebo median 
adherence 78% (35-98%) 
8 patients took less than 75% of metformin 
ANALYSIS: ITT:  T-tests (cross-over study)  
Post-randomization exclusions? No 
ADEQUATE 
RANDOMIZATION:
Yes 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Yes 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
Yes 
ATTRITION: Overall: 4 (1 in group A, 3 in group B)  
Nonadherence to therapy or social circumstances 
NOTES: 2 without full set of insulin sensitivity data because of IV 
access, but does not affect key question of SR 
Adjusted for puberty and poor adherence to therapy on insulin 
sensitivity 
QUALITY RATING Good 
 
 
 
 
STUDY Author: Williamson et al58 
Year: 2006 
FUNDING: NIH 
RESEARCH 
OBJECTIVE: 
Assess efficacy of internet-based lifestyle intervention program 
in obese African-American girls 
METHODS:  
PARTICIPANTS: N = 57; African-American females; ages 11 – 15; overweight or 
obese with BMI > 85th percentile for age and sex; at least one 
obese (BMI > 30) biological parent and one overweight (BMI > 
27) parent willing to participate in study 
INTERVENTION: Interactive behavioral internet program (treatment) vs. internet 
health education program (control) over 24 months. 
Treatment arm included nutrition education and internet 
counseling behavior modification program focused on eating 
habits and physical activity, in addition to 4 face-to-face 
counseling sessions during the first 12 weeks.  Control arm 
included education on healthy nutrition and exercise, but no 
counseling or recommended behavioral changes (passive).  
OUTCOME Measured at 6, 12, 28 and 24 months 
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ASSESSMENT: BMI, %BMI, DXA, weight loss behavior scale, web site use 
(log on required),  
RESULTS:* Treatment: BMI +0.73 ± 0.66, %BMI – 0.004 ± 0.003 
Control: BMI +1.2 ± 0.65, %BMI – 0.001 ± 0.003 
Significant difference in % body fat seen in first 6 months, but 
did not significantly differ at 2 years.   
ADVERSE 
EVENTS: 
None reported 
ADHERENCE/ 
COMPLIANCE: 
100% attendance for completers at face-to-face counseling 
sessions 
Self-report for exercise, eating habits 
ANALYSIS: ITT: Yes 
Post-randomization exclusions? No 
ADEQUATE 
RANDOMIZATION:
Not reported 
ADEQUATE 
ALLOCATION 
CONCEALMENT: 
Not possible 
BLINDING OF 
OUTCOMES 
ASSESSORS: 
No 
ATTRITION: 17 (7 control, 10 treatment) 
70% completion rate (adolescent-parent dyads) 
NOTES: Limiting factor for external validity: family willing to pay $300 
towards purchase of computer (worth $1000); home with 
electricity and at least one functional telephone line (program 
included free internet access) 
QUALITY RATING Poor 
*Adolescent participant results only reported.  Did not include parental results. 
 
 
  
